MA42532B1 - Antibody constructs for flt3 and cd3 - Google Patents

Antibody constructs for flt3 and cd3

Info

Publication number
MA42532B1
MA42532B1 MA42532A MA42532A MA42532B1 MA 42532 B1 MA42532 B1 MA 42532B1 MA 42532 A MA42532 A MA 42532A MA 42532 A MA42532 A MA 42532A MA 42532 B1 MA42532 B1 MA 42532B1
Authority
MA
Morocco
Prior art keywords
antibody construct
flt3
relates
polynucleotide
antibody constructs
Prior art date
Application number
MA42532A
Other languages
French (fr)
Other versions
MA42532A (en
Inventor
Peter Kufer
Tobias Raum
Patrick Hoffmann
Jochen Pendzialek
Claudia Bluemel
Christoph Dahlhoff
Elisabeth Nahrwold
Franziska Bott
Markus Muenz
Johannes Brozy
Matthias Friedrich
Benno Rattel
Pamela Bogner
Andreas Wolf
Cornelius Pompe
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Priority claimed from PCT/EP2016/068319 external-priority patent/WO2017021362A1/en
Publication of MA42532A publication Critical patent/MA42532A/en
Publication of MA42532B1 publication Critical patent/MA42532B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

La présente invention concerne une construction d'anticorps bispécifique comprenant un premier domaine de liaison qui se lie à la flt3 humaine sur la surface d'une cellule cible et un second domaine qui se lie au cd3 humain sur la surface d'un lymphocyte t. L'invention concerne également un polynucléotide codant pour cette construction d'anticorps, un vecteur comprenant ledit polynucléotide et une cellule hôte transformée ou transfectée avec ledit polynucléotide ou ledit vecteur. Par ailleurs, l'invention concerne un procédé de production de la construction d'anticorps susmentionnée, une utilisation médicale de cette construction d'anticorps et une trousse comprenant ladite construction d'anticorps.The present invention relates to a bispecific antibody construct comprising a first binding domain that binds human flt3 on the surface of a target cell and a second domain that binds human cd3 on the surface of a t cell. The invention also relates to a polynucleotide encoding this antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or said vector. Furthermore, the invention relates to a method for producing the aforementioned antibody construct, a medical use of this antibody construct and a kit comprising said antibody construct.

MA42532A 2015-07-31 2016-08-01 Antibody constructs for flt3 and cd3 MA42532B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199944P 2015-07-31 2015-07-31
PCT/EP2016/068319 WO2017021362A1 (en) 2015-07-31 2016-08-01 Antibody constructs for flt3 and cd3

Publications (2)

Publication Number Publication Date
MA42532A MA42532A (en) 2018-06-06
MA42532B1 true MA42532B1 (en) 2023-05-31

Family

ID=60245275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42532A MA42532B1 (en) 2015-07-31 2016-08-01 Antibody constructs for flt3 and cd3

Country Status (2)

Country Link
AR (1) AR105561A1 (en)
MA (1) MA42532B1 (en)

Also Published As

Publication number Publication date
AR105561A1 (en) 2017-10-18
MA42532A (en) 2018-06-06

Similar Documents

Publication Publication Date Title
MA42530B1 (en) Constructions of Bispecific Antibodies Binding to dll3 and cd3
CL2020000938A1 (en) Anti-tigit antibodies, their compositions and use. (divisional request 201800744)
CY1126145T1 (en) ANTIBODY CONSTRUCTS FOR FLT3 AND CD3
EA201890382A1 (en) ANTIBODY CONSTRUCTIONS FOR CD70 AND CD3
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
EA201890383A1 (en) CONSTRUCTIONS OF BISPECIFIC ANTIBODIES CONNECTING WITH MEZOTELIN AND KD3 (CD3)
EA201890390A1 (en) BISPECIFIC ANTIBODY STRUCTURES CONNECTING EGFRvIII and CD3
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
MX2018015271A (en) Anti-b7-h3 antibodies and antibody drug conjugates.
WO2017123650A3 (en) Multivalent and multispecific 41bb-binding fusion proteins
MA44594B1 (en) Anti-ctla-4 Antibodies and Methods of Use thereof
EA201792583A1 (en) METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS
MX2018005389A (en) Non-human animals having a humanized lymphocyte-activation gene 3.
EA201792193A1 (en) CONSTRUCTIONS OF BISPECIFIC ANTIBODIES FOR CDH3 AND CD3
UA116614C2 (en) FACTOR ANTIBODY AND ITS APPLICATION
MX2018015285A (en) Anti-b7-h3 antibodies and antibody drug conjugates.
PH12021550764A1 (en) Trem2 stabilizing antibodies
EA202190609A1 (en) ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G
MX2018015277A (en) Anti-b7-h3 antibodies and antibody drug conjugates.
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
BR112018067479A2 (en) antibody, antigen binding fragment of an antibody, chimeric molecule, chimeric antigen receptor, polynucleotide, cell, methods for preparing chimeric antigen receptor, for making an antibody, and for determining the presence of cd127 + cells, pharmaceutical composition, medium combination therapy, diagnostic method, and use of an anti-cd127 antibody or antigen-binding fragment thereof
EA202191785A1 (en) ANTIBODIES TO CTLA4 AND METHODS OF THEIR APPLICATION
MA39342B2 (en) Il -21 antibody
EA201892440A1 (en) ANTIBODIES TO TL1A AND THEIR APPLICATIONS
CO2022004797A2 (en) Anti-klk7 antibodies, anti-klk5 antibodies, anti-klk5/klk7 multispecific antibodies and methods of use